Marcain Polyamp Steripack

Bupivacaine Hydrochloride, the active ingredient in Marcain Polyamp Steripack, is a local anesthetic (amide) presented as a sterile solution for infiltration use. It provides regional nerve block and infiltration anesthesia for surgical and procedural pain control.

GNH USA supplies Marcain Polyamp Steripack as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bupivacaine Hydrochloride is used as a local anesthetic for procedures requiring nerve block or tissue infiltration.

Surgical procedures: provides prolonged anesthesia for incision and tissue dissection Dental procedures: enables pain control during extractions and periodontal surgery Obstetric procedures: offers anesthesia for episiotomy or perineal repair

Adverse reactions may occur following administration of bupivacaine.

Common Side Effects: - Transient numbness at the injection site - Mild burning or tingling sensation - Hypotension - Bradycardia - Dizziness or light‑headedness - Nausea

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia - Seizures, especially with high plasma concentrations - Methemoglobinemia - Allergic reactions ranging from rash to anaphylaxis - Respiratory depression - Persistent neurologic deficits (rare)

Prior to use, clinicians should evaluate patient‑specific risk factors and follow safe handling practices.

Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics Cardiovascular status: avoid in patients with severe heart block or conduction disorders Dosage limits: adhere to recommended maximum dose based on patient weight and site Concurrent CNS depressants: use caution with agents that lower seizure threshold Pregnancy and lactation: assess risk–benefit, limited data available Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bupivacaine may interact with other drugs that affect cardiac or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase cardiotoxicity risk - Beta‑blockers: may exacerbate bradycardia and hypotension - General anesthetics (e.g., halothane): potentiate CNS depression

Moderate Interactions (Monitor Closely): - Opioids: additive sedation and respiratory depression - Muscle relaxants: enhanced neuromuscular blockade - Other local anesthetics: cumulative systemic toxicity